Dr. Jeff Leiden currently serves as Executive Chairman at Vertex Pharmaceuticals and was Chief Executive Officer and President from 2012 through March 2020. Prior to joining Vertex, Dr. Leiden was a managing director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President, Chief Operating Officer and Chief Scientific Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the board of directors of Abbott Laboratories from 2000 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments at the University of Chicago, the Harvard School of Public Health, and at Harvard Medical School. Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company and as chairman of Odyssey Therapeutics, a privately held company developing novel medicines for the treatment of cancer and autoimmune diseases and Casana Health, a privately held home-health monitoring company. He is also chairman of the board of Revolution Healthcare (REVH), a SPAC focused on companies that utilize novel technologies to revolutionize the treatment and delivery of mental healthcare. He is also a member of the MIT CEO Advisory Board, a member of the Harvard Medical School Board of Fellows, and chairman of the Massachusetts Competitive Partnership (MACP).